ESPE2022 Poster Category 1 Diabetes and Insulin (86 abstracts)
Symptoms and Glycemic Control in Young People with Type 1 Diabetes following SARS-CoV-2 Infection: an Observational Study
Revital Nimri 1,2 , Marianna Rachmiel 3,2 , Michal Yackobovitch-Gavan 1,2 , Avivit Brener 4,2 , Liat de Vries 1,2 , Naama Fisch Shvalb 1 , Liora Lazar 1,2 , Asaf Oren 4 , Talia Jacobi-Polishook 3 , Noa Shefer Averbuch 1,2 , Ariel Tenenbaum 1,2 , Eran Mel 1 , Sari Krepel Volsky 1 , Marie Mouler 1 , Sharon Demol 1 , Shlomit Shalitin 1,2 , Rachel Bello 1 , Moshe Phillip 1,2 & Yael Lebenthal 4,2
1The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Pediatric Endocrinology and Diabetes Institute, Shamir (Assaf Harofeh) Medical Center, Tzrifin, Israel; 4Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Objective: To describe clinical manifestations of SARS-CoV-2 infection in children, adolescents, and young adults with established type 1 diabetes and explore the effects of COVID-19 on glycemic control and disease course.
Methods: Observational study conducted at three pediatric diabetes clinics in Israel between mid-March-2020 and mid-March-2021. Included were young people with established type 1 diabetes, <30years, who tested positive for SARS-CoV-2 (qRT-PCR). Data was collected from medical files, diabetes devices, and COVID-19 questionnaire. Outcome measures were analyzed by presence/absence of clinical symptoms (symptomatic/asymptomatic) and by age group (Pediatric, <19years/young adults, 19-30years).
Results: Of 132 patients, mean age 16.9±5.3years, with COVID-19 confirmed infection, 103 (78%) had related symptoms; the most common were headaches, fatigue, fever and loss of sense of smell. All had mild disease course, but four required hospitalization and two cases were directly related to COVID-19 infection (Pleuropneumonia in a patient with immunodeficiency syndrome, one case of diabetic-ketoacidosis). Logistic regression analysis showed that age (OR=1.11, 95%CI, 1.01, 1.23; P=0.033), elevated glucose levels (OR=5.23, 95%CI, 1.12, 24.41; P=0.035) and comorbidities (OR=8.21, 95%CI, 1.00, 67.51; P=0.050) were positively associated with symptomatic infection. Persistent symptoms occurred in 16.5% of the cohort over a median of 6.7 months; age (OR=1.14, 95%CI, 1.01, 1.29; P=0.030) and elevated glucose levels (OR=3.42, 95%CI, 1.12, 10.40; P=0.031) were positively associated with persistent symptoms. Usually, no change was reported in glucose levels (64%) except for a temporary deterioration in glycemic control during the short infection period.
Conclusions: Young people with established type 1 diabetes experience mild COVID-19 infection. Elevated glucose levels during COVID-19 infection and older age were associated with prolonged disease course.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more